Published in final edited form as:

J Alzheimers Dis. 2019 ; 70(4): 1175–1185. doi:10.3233/JAD-190190.

Inhibition of Histone Methyltransferases EHMT1/2 Reverses β Amyloid-Induced Loss of AMPAR Currents in Human Stem Cell-Derived Cortical Neurons

Lin Lin^{1,*}, Aiyi Liu^{1,*}, Hanqin Li^{1,2,*}, Jian Feng^{1,2}, Zhen Yan^{1,2,#}

¹Department of Physiology and Biophysics, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, NY 14214, USA

²Veterans Affairs Western New York Healthcare System, Buffalo, NY 14215

Abstract

Emerging evidence suggests that epigenetic dysregulation of gene expression is one of the key molecular mechanisms of neurodegeneration and Alzheimer's disease (AD). However, little is known about the role of epigenetic dysregulation on synaptic dysfunction in humans, because of the difficulties of obtaining live human neurons. Here we generated mature human cortical neurons differentiated from human embryonic stem cells, and exposed them to β -amyloid ($A\beta$). We found that the histone methyltransferase, EHMT1, which catalyzes histone lysine 9 dimethylation (H3K9me2, a mark for gene repression), was significantly elevated in $A\beta$ -treated human stem cell-derived neurons. $A\beta$ treatment led to a significant reduction of AMPA receptor-mediated whole-cell current and excitatory postsynaptic current (EPSC). Application of BIX01294, a selective inhibitor of EHMT1/2, restored AMPAR currents and glutamatergic synaptic transmission in $A\beta$ -treated human cortical neurons. These results suggest that inhibition of the aberrant histone methylation is a novel approach to reverse $A\beta$ -induced synaptic deficits in human neurons.

Keywords

Alzheimer's disease; human stem cell-derived neurons; histone methyltransferase; histone dimethylation; EHMT1; epigenetics; AMPA receptor; β -amyloid

INTRODUCTION

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in the world. One of its hallmarks is the presence of amyloid plaques in brain regions like cerebral cortex and hippocampus [1,2]. A large body of literatures has shown that $A\beta$ oligomers may play a central role in synapse damage underlying the cognitive deficits of AD [3–5]. Mutations in Amyloid Precursor Protein (APP) that result in the excessive accumulation of $A\beta$ have been linked to a subset of familial AD [6,7]. Despite the intensive studies in rodent animal

#Correspondence should be addressed to Z. Y. (zhenyan@buffalo.edu).

*These authors contributed equally.

models, little research has been done to examine the impact of A β on synaptic function in humans, because of the difficulties of obtaining live human neurons.

Rapid development of the field of human pluripotent stem cells (hPSCs), especially *in vitro* neural differentiation, offers an unprecedented approach to generate unlimited amount of human neurons. Robust differentiation protocol from hPSCs to cortical neuron has been well developed during the past two decades [8–11]. In a pioneer study, cortical neurons derived from familiar AD patient-specific induced pluripotent stem cells (iPSCs), which carry mutations in presenilin 1 and presenilin 2, exhibit increased A β secretion [12]. Neurotoxicity and synaptotoxicity of A β were also observed in human iPSC-derived neurons [13,14], which enforces the long-holding A β toxicity hypothesis in the etiology of AD [5,15,16]. The success of hPSC-derived cortical neurons in recapitulating major AD pathologies suggests that they can serve as a more biologically and clinically relevant system in AD research, comparing to the conventional overexpression-based animal models [17,18].

Despite a few identified AD-related genetic risk factors, the lack of a genetic basis for the majority of this disease intrigues academic to find alternative etiology for AD. Emerging evidence suggests that epigenetic dysregulation of gene expression may play a key role in aging and neurodegeneration [19–22]. Histone methylation is one of the epigenetic mechanisms to control gene expression. Through adding or removing methyl groups on Lysine (K) residues of histones by histone methyltransferases or histone demethylases, the structure of chromatin is dynamically remodeled to allow or stop access of transcription regulatory proteins to genomic DNA, thus leading to gene activation or repression [23,24]. Here we generated human embryonic stem (hES) cells-derived cortical neurons, and examined the potential of targeting histone methylation enzymes in rescuing glutamate receptor function in these human neurons exposed to A β .

MATERIALS AND METHODS

Differentiation of Human ES Cells to Forebrain Neurons

Human ES cells (H9, WiCell, Wisconsin) were routinely maintained on feeder cells in hESC medium (DMEM/F12 supplemented with 20% knockout serum replacement, 0.1 mM nonessential amino acids (NEAA), 1x Penicillin/Streptomycin, 0.1 mM 2-Mercaptoethanol, 0.2 mM glutamine, 4 ng/ml bFGF) and passaged with 1 mg/ml dispase (Stemcell Technologies) every 7 days. Neural differentiation was performed using previously published protocols [8,25] with modification. Briefly, hESCs around passage 30 were dissociated with 1 mg/ml dispase into small clumps which were gently transferred to non-treated EasYflasks (Nunc, cat# 169900) to form embryoid bodies (EB) in EB medium (DMEM/F12 supplemented with 20% knockout serum replacement, 0.1 mM nonessential amino acids (NEAA), 1x Penicillin/Streptomycin, 10 μ M SB431542 and 5 μ M Dorsomorphin) for 6 days. Then EBs were plated on Matrigel-coated 6-well plates in N2 Medium (DMEM/F12 with 1 $\times$ N2 supplements, 0.1 mM NEAA, 10 ng/ml bFGF) for two weeks. Well-formed rosettes were isolated manually, dissociated with TrypLE and expanded in N2 medium on matrigel-coated plate. Upon reaching confluence, cells were dissociated with TrypLE into single cells and plated on polyornithine/matrigel-coated cover slips at 1×10^5 – 2×10^5 /cm² in neural differentiation medium containing: Neurobasal, 1 $\times$ B27

supplements, GDNF (20 ng/ml), BDNF (20 ng/ml), NGF (20 ng/ml), ascorbic acid (200 μ M), dcAMP (0.5mM). DAPT (2.5 μ M) was added 7 days later. Medium was half changed every other day.

Rat Primary Neuronal Culture

Rat frontal cortical cultures were prepared as described previously [26]. All experiments were carried out with the approval of State University of New York at Buffalo Animal Care Committee. Briefly, pregnant Sprague-Dawley rats were anaesthetized with isoflurane vapour and immediately sacrificed. Frontal cortex of rat embryos (E18) was dissected and cells were dissociated using trypsin and trituration through a Pasteur pipette. Neurons were plated on coverslips coated with poly-L-lysine in DMEM with 10% fetal calf serum at a density of 1×10^5 cells/cm². When neurons attached to the coverslip within 24 hours, the medium was changed to neurobasal media (Invitrogen) with B27 supplement. Cytosine arabinoside (Arac, 1.25 μ M) was added to culture media at DIV3 to stop glial proliferation. Neurons were maintained for 2 weeks before being used.

A β and BIX01294 Treatment

Pre-aggregated A β ₁₋₄₂ peptides (Anaspec, AS72216) and BIX01294 (Sigma, B9311) was directly dissolved with PBS. Rat or human cortical cultures were subjected to A β (1 μ M) treatment for 3 days with or without overnight BIX01294 treatment (0.1 μ M for rat cortical cultures, 0.25 μ M or 0.5 μ M for human cortical cultures, added after A β treatment). BIX01294 was used as a specific EHMT1/2 inhibitor, because it specifically inhibits EHMT2 (G9a) and EHMT1 (GLP) with no significant activity at other histone methyltransferases [27].

Immunocytochemistry

Immunocytochemical staining of human neurons used similar procedures as we described previously [28]. Human ES cell-derived cortical cultures (DIV120) were fixed in 4% paraformaldehyde in phosphate buffered saline (PBS) for 20 min at room temperature and washed 3 times with PBS. After permeabilization with 0.1% Triton X-100 in PBS for 15 min, neurons were incubated with 5% bovine serum albumin for 1 h to block nonspecific staining. Next, neurons were incubated with primary antibodies at 4°C overnight, including anti-Pax6 (1:200, Developmental Studies Hybridoma Bank, AB528427), anti-Nestin (1:5000, Millipore, abd69), anti-Tuj1 (1:1000; Abcam, ab78078), anti-MAP2 (1:500; Santa Cruz, SC74421) and anti-vGluT1 (1:1000; Synaptic System, 135-303). After washing, neurons were incubated with Alexa Fluor 594- or Fluor 488-conjugated secondary antibody (1:2000, Thermo Fisher) for 2 h at room temperature. After washing in PBS for three times, cell nuclei were visualized with DAPI (Sigma Aldrich, 1:10,000) and coverslips were mounted on slides with VECTASHIELD mounting medium (Vector Laboratories, Burlingame, CA). Fluorescence images were obtained using a 20 $\times$ or 40 $\times$ lens and were captured digitally using SPOT basic image capture software.

Real-time RT-PCR

Cultured neurons were lysed in cold Trizol reagent (Invitrogen) to extract total RNA. Then, the cDNA was obtained using iScript cDNA Synthesis Kit (Bio-Rad) and real-time PCR was performed using iQSYBR Green Supermix (Bio-Rad CFX96 Touch system) according to the manufacturer's instruction. Fold changes in the target gene expression was determined by normalized CT value ($2^{-\Delta CT}$), $CT = CT_{\text{target}} - CT_{\text{GAPDH}}$, and $\Delta CT = CT_{\text{A}\beta} - CT_{\text{Con}}$, GAPDH was used as housekeeping gene; CT means threshold cycle, which is defined as the cycle number getting detectable fluorescence signal. A PCR mixture of 20 μl per well (96-well thin-wall PCR plate, Bio-Rad) was amplified according to the following cycling condition: 95°C for 5 min, followed by 40 cycles of 95°C for 30 s, 55°C for 30 s and 72°C for 60 s. Quantitative real-time PCR was performed in double reactions. The sequences of primers were as follows: human EHMT1: 5'-GGACGGAATTGACCCCAACT, 5'-AATATTAGCGCC-CGCCTGAA; human EHMT2: 5'-TCCAGCATTTCCGCATGAGTGA, 5'-CAACTGTTTCAG-CTAGAGCTTCG; human GAPDH: 5'-GACAACAGCCTCAAGATCATCAG, 5'-ATGGCATGGACTGTGGTCATGAG; rat EHMT1: 5'-CATAGCAAAAGCAGACACGA, 5'-ACTTTCCAAGGTTTCCTTTC; rat EHMT2: 5'-TCCAGCATTTCCGCATGAGTGA, 5'-CAACTGTTTCAGCTAGAGCTTCG; rat GAPDH: 5'-GACAACTCCCTCAAGATTGTCAG, 5'-ATGGCATGGACTGTGGTCATGAG.

Electrophysiology in Human Cortical Cultures

Human ES-derived cortical neurons (DIV110-140) were used to measure ionic currents (voltage-dependent sodium, potassium and calcium currents), synaptic currents (AMPA- and NMDAR-mediated currents, spontaneous and miniature EPSC), action potentials and network activity using whole-cell voltage-clamp or current-clamp techniques as we previously described [29–32]. The long-term culture was used because only at this stage, all the electrophysiological properties of mature cortical neurons could be reliably detected in most of the recorded neurons. Recordings were obtained with an Axon Instruments 200B amplifier that was controlled and monitored by an IBM PC running pClamp 10.0 with a DigiData 1320 series interface (Axon instruments). Tight seals (2-10 G Ω) from visualized neurons were obtained by applying negative pressure. With additional suction, the membrane was disrupted into the whole-cell configuration following series resistance (4-10 M Ω) compensation (70-90%).

For the recording of voltage-dependent sodium, potassium and calcium currents, cells (held at -70 mV) were depolarized by brief pulses of voltage steps (-90 mV to +50 mV) or a ramp protocol. For the recording of APs, membrane potentials were kept at -70 mV, and a series of hyperpolarizing and depolarizing step currents were injected. Spontaneous APs were recorded with cells (held at -55 mV) without current injection. AMPAR and NMDAR-mediated currents were evoked by application of AMPA (100 μM) or NMDA (100 μM) for 2 sec every 30 sec in neurons held at -70 mV. Drugs were delivered with a "sewer pipe" system. The array of drug capillaries (~150 μm inner diameter) was positioned a few hundred microns from the cell under recording. Solution changes were controlled by the SF-77B fast-step solution stimulus delivery device (Warner Instruments). Neurons were

perfused with ACSF (in mM): 130 NaCl, 26 NaHCO₃, 3 KCl, 1 CaCl₂, 5 MgCl₂, 1.25 NaH₂PO₄, 10 Glucose, pH 7.4, 300 mOsm, bubbled with 95% O₂ and 5% CO₂.

For the recording of voltage-dependent Na⁺, K⁺, Ca²⁺ currents, and APs, internal solution contained (in mM): 60 K₂SO₄, 60 N-methyl-D-glucamine, 20 HEPES, 1 MgCl₂, 0.5 EGTA, 12 phosphocreatine, 2 Na₂ATP, 0.2 Na₂GTP and 0.1 leupetin, pH 7.2-7.3, 265-270 mOsm. External solution was ACSF. A modified ACSF (3 mM CaCl₂, 20 mM CsCl, 0.5 μM TTX) was used for Ca²⁺ current recordings.

For the recording of AMPAR- or NMDAR-mediated ionic currents, internal solution contained (in mM): 180 N-methyl-D-glucamine, 4 MgCl₂, 40 HEPES, 0.5 BAPTA, 12 phosphocreatine, 3 Na₂ATP, and 0.5 Na₂GTP, pH 7.2-7.3, 265-270 mOsm. External solution for AMPAR current recording contained (in mM): 127 NaCl, 20 CsCl, 1 MgCl₂, 10 HEPES, 5 BaCl₂, 12 glucose, 0.001 TTX, pH 7.3-7.4, 300-305 mOsm. External solution for NMDAR current recording was the same except for the removal of MgCl₂ and the addition of 1 mM CaCl₂ and 20 μM glycine.

For sEPSC and network activity measurements, cells were held at -70 mV. Internal solution contained (in mM): 130 cesium methanesulfonate, 10 CsCl, 4 NaCl, 1 MgCl₂, 10 HEPES, 5 EGTA, 2.2 lidocaine, 12 phosphocreatine, 5 MgATP, 0.5 Na₂GTP, 0.1 leupeptin, pH 7.2-7.3, 265-270 mOsm. External solution contained (in mM): 127 NaCl, 5 KCl, 2 MgCl₂, 2 CaCl₂, 12 glucose, 10 HEPES, pH 7.3-7.4, 300-305 mOsm. Tetrodotoxin (TTX, 0.5 μM) was added for mEPSC recordings.

Data analyses were performed with Clampfit (Axon instruments), Mini Analysis Program (Synaptosoft, Leonia, NJ) and Kaleidagraph (Albeck Software).

Electrophysiology in Rat Cortical Cultures

Cultured rat cortical neurons (DIV 16-21) were used for whole-cell recordings of AMPAR-mediated ionic and synaptic currents with standard voltage-clamp techniques as we previously described [28]. Neurons were perfused with background solution containing (in mM): 140 NaCl, 2 KCl, 2 MgCl₂, 1 CaCl₂, 15 HEPES, 23 glucose, pH 7.3-7.4, 300-305 mOsm. Internal and external solutions for recording AMPAR-mediated ionic currents and mEPSC were the same as those used in human neurons.

Statistics

All data are expressed as mean ± s.e.m. Statistical analysis for experiments with two groups was performed using Student's t-test. Experiments with more than two groups were subjected to one-way or two-way ANOVA, followed by Bonferroni's post hoc tests using Prism 5.0 (GraphPad Software).

RESULTS

Generation and characterization of human cortical neurons differentiated from human embryonic stem cells

Human embryonic stem (hES) cells were cultured and differentiated using an embryoid body (EB)-based system [8,25]. The hES cells (Figure 1A) were first differentiated to EBs (Figure 1B). After the initial differentiation, EBs were plated on matrigel-coated plates to enable the formation of neuroepithelial rosettes that express neuroectodermal differentiation marker Pax6 (paired box protein 6) and neuronal stem cell marker Nestin (Figure 1C, 1E). Cells from these rosettes were continually cultured and further differentiated into forebrain cortical neurons (Figure 1D). After 8-10 weeks of *in vitro* cultivation, matured neurons were immunocytochemically stained for the neuronal marker Tuj1 (neuron-specific β -III Tubulin), dendritic marker of matured neurons MAP2 and glutamatergic neuronal marker vGluT1 (vesicular glutamate transporter 1) (Figure 1F, 1G). The positive staining of these markers indicated that we successfully differentiated hES into matured glutamatergic neurons.

Next, electrophysiological recordings were performed to test whether these human neurons (~DIV110) were functionally active. We found that most of the neurons exhibited voltage-dependent Na^+ and K^+ currents (90% of recorded cells, $n=27$, Figure 2A), voltage-dependent Ca^{2+} current (Figure 2B), and action potentials elicited by depolarizing current pulses (75% of recorded cells, $n=23$, Figure 2C), indicating that the intrinsic membrane properties of these human neurons are normal. AMPAR-mediated and NMDAR-mediate currents were also observed (Figure 2D), indicating the presence of ligand-gated receptor channels in the human neurons. Moreover, spontaneous excitatory postsynaptic currents (sEPSC) and miniature EPSC (Figure 2E) were found in 75% of recorded cells ($n=22$). The cortical neuron-specific rhythmic network activity (Figure 2F) and the synaptic-driven spontaneous action potentials (sAP) (Figure 2G) were also detected (50% of recorded cells, $n=16$), indicating the formation of glutamatergic synaptic connections and transmission in these human neurons. Taken together, the data confirm that all the major features of mature glutamatergic neurons are present in the generated human neurons, which makes them a valid *in vitro* system.

Alteration of histone methyltransferases by A β treatment in human and rodent neurons

To study the pathophysiological basis and treatment strategy of AD using the generated human neurons, we exposed them to A β , since A β oligomers have been found to induce synaptic dysfunction and cognitive impairments in rodent models [3–5]. Postmortem studies of AD human brains have found elevated H3K9me2, a repressive histone mark, in the cortex [33,34], so we examined the mRNA level of *EHMT1/2*, the H3K9me2-catalyzing enzyme, in mature hES-derived cortical neurons exposed to A β (1 μM) for 3 days [28]. The qPCR assays indicated that *EHMT1* mRNA was significantly increased in A β -treated human neurons (Figure 3A, 1.42 ± 0.13 of control, $n=5$, $p<0.05$, t-test). Similarly, A β treatment significantly elevated the mRNA level of *EHMT1* and *EHMT2* in rat cultures (Figure 3B, *EHMT1*: 1.42 ± 0.18 of control, *EHMT2*: 1.29 ± 0.11 of control, $n=6$, $p<0.05$, t-test).

Loss of AMPAR currents by A β treatment and its rescue by an EHMT inhibitor in human and rodent neurons

Next, we examined the A β -induced alteration of whole-cell AMPAR current and its normalization by EHMT1/2 inhibitor in human neurons. As shown in Figure 4A and 4B, AMPAR-mediated ionic current density (pA/pF) was significantly decreased in A β -exposed human neurons (Con: 15.68 ± 1.62 , n=22; A β : 6.60 ± 0.70 , n=20, $p < 0.001$, ANOVA). Treatment with the specific EHMT1/2 inhibitor BIX01294 (0.5 μ M, 12 hrs) [27] significantly increased AMPAR current density (A β +BIX01294: 12.42 ± 1.95 , n=22; Con+BIX01294: 17.04 ± 1.95 , n=17), bringing it close to the control level. Consistently, in rat cortical cultures, A β significantly decreased AMPAR current density, which was rescued by subsequent BIX01294 treatment (Figure 4C and 4D, Con: 28.09 ± 1.78 , n=26; A β : 16.86 ± 1.77 , n=24; A β +BIX01294: 23.94 ± 1.75 , n=23; Con+BIX01294: 26.53 ± 2.43 , n=18, $p < 0.001$, ANOVA).

To find out the impact of A β and BIX01294 on glutamatergic synaptic transmission in human cortical neurons, we examined AMPAR-mediated excitatory postsynaptic currents (EPSC). As shown in Figure 5A and 5B, A β -treated human cortical neurons exhibited significantly decreased spontaneous EPSC (sEPSC) frequency and amplitude (Frequency, Con: 3.31 ± 0.99 Hz, n=8; A β : 0.48 ± 0.10 Hz, n=8, $p < 0.05$, ANOVA; Amplitude, Con: 17.14 ± 0.58 pA, n=8; A β : 11.52 ± 0.53 pA, n=8, $p < 0.001$, ANOVA). Subsequent treatment with BIX01294 induced a complete recovery of sEPSC frequency and a slight increase of sEPSC amplitude (Frequency, A β +BIX01294: 3.07 ± 0.70 Hz, n=9; Amplitude, A β +BIX01294: 13.00 ± 1.29 pA, n=9). Miniature EPSC (mEPSC), a synaptic response resulting from quantal release of single glutamate vesicles, showed a marked reduction in its frequency by A β treatment, which was dramatically restored by BIX01294 treatment in human neurons (Figure 5C and 5D, Con: 3.15 ± 0.70 Hz, n=9; A β : 0.85 ± 0.14 Hz, n=8; A β +BIX01294: 2.79 ± 0.43 Hz, n=8, $p < 0.01$, ANOVA). The amplitude of mEPSC was not significantly altered by A β and BIX01294 in human neurons (Con: 10.61 ± 0.38 pA, n=9; A β : 10.49 ± 0.39 pA, n=8; A β +BIX01294: 10.39 ± 0.39 pA, n=8). Similarly, in A β -treated rat cortical cultures, BIX01294 successfully rescued mEPSC frequency and amplitude (Figure 5E and 5F, Con: 5.72 ± 1.05 Hz, 28.95 ± 1.66 pA, n=16; A β : 0.78 ± 0.21 Hz, 22.68 ± 1.54 pA, n=11; A β +BIX01294: 5.55 ± 1.54 Hz, 25.01 ± 1.06 pA, n=11; Con+BIX01294: 4.61 ± 0.98 Hz, 26.03 ± 1.44 pA, n=17, $p < 0.05$, ANOVA).

DISCUSSION

Most of AD research is based on animal models, which has provided insights into the pathogenic mechanisms and drug targets for this neurodegenerative disease. However, human conditions cannot be entirely recapitulated in rodents. The translational value of animal models could be enhanced when combined with *in vitro* models derived from patient-specific iPSCs and isogenic controls generated using CRISPR/Cas9 genome editing [17,35]. Induced neurons from FAD patients carrying risk factors, such as mutant presenilins or APOE $\epsilon 3/4$ allele, recapitulate pathological signatures of AD [12,36]. Human PSC-derived cortical neuronal precursors transplanted into the brain of a murine AD model display human-specific pathological features, including abnormal Tau and

neurodegeneration [37]. By using a frontotemporal dementia patient-derived iPSC carrying the Tau P301L mutation and the isogenic lines in which p35 is replaced with a noncleavable mutant, researchers have confirmed the role of p25/Cdk5 in tauopathy [38]. Thus, human stem cell-derived neurons offer a new platform for investigating molecular mechanisms of AD and identifying therapeutic agents [39,40]. However, the heterogeneity of the human population, the extended temporal course of the disease, and the accurate modeling of common non-familial “sporadic” forms of AD remain challenges for human reprogramming-based cell models [17].

Genetic and epigenetic variation associated with the initiation and progression of Alzheimer’s disease can also be investigated using induced pluripotent stem cells [41]. Epigenetic mechanisms have been proposed to play a key role in the deregulation of vulnerability genes underlying AD pathogenesis [20,42]. Animal studies suggest that histone post-translational modifications, particularly histone acetylation, are prospective drug targets for AD [43–46]. Histone methylation marks and enzymes are implicated in senescence and cognitive functioning [47], but their links with AD await to be firmly identified [20,45]. Human postmortem studies have found aberrant histone methylations at frontal cortex of AD patients [33,48], suggesting that targeting histone methylation is a new avenue to treat AD-related abnormalities.

In the current study, we have used A β exposure of human cortical neurons differentiated from hES cells as an *in vitro* model for sporadic AD. Choosing this system instead of human iPSCs is based on several considerations. First, H9 hES cells are the gold standard in stem cell research widely used in a variety of studies. Data generated on H9 hES cells can be readily compared to data generated on the same cells by other investigators. Second, the diverse genetic background of idiopathic AD patients makes it hard to use patient-specific iPSCs to compare with those from normal control subjects. Third, as idiopathic AD has complex and unclear genetic contributions, it is not possible to generate isogenic control lines. Fourth, even if iPSCs from AD patients with monogenic mutations are used, it is unclear whether the results are generally applicable to idiopathic AD. In this study, we have demonstrated that EHMT1 mRNA is significantly increased in A β -treated human neurons, and the A β -induced impairment of AMPAR-mediated ionic currents and synaptic transmission is rescued by *in vitro* treatment with an EHMT1/2 inhibitor. The potential relevance of these findings to AD treatment is confirmed by our recent study in a familial AD mouse model carrying APP mutations, which shows that *in vivo* administration of EHMT1/2 inhibitors rescues synaptic and cognitive deficits by restoring glutamate receptor expression [34]. Our current results have further validated the potential of using human stem cell-derived neurons for disease modeling and drug discovery.

In rodent neurons, A β is found to impair glutamatergic signaling by affecting presynaptic vesicle cycling [49,50] and disrupting postsynaptic AMPAR trafficking [28,51]. In human stem cell-derived neurons, the A β -induced substantial reduction of sEPSC and mEPSC frequency suggests a presynaptic and a possible postsynaptic component, while the A β -induced reduction of AMPAR ionic current suggests a postsynaptic component. The restoration of glutamatergic transmission in human neurons by EHMT1/2 inhibitor is likely achieved by the collective upregulation of the transcription of multiple presynaptic and

postsynaptic genes. Human studies have revealed the causal role of EHMT1 in intellectual disability [52,53]. Our current study suggests that targeting EHMT1/2-associated chromatin-modification module might also be able to restore transcriptional homeostasis and synaptic function in neurodegenerative disorders.

ACKNOWLEDGMENTS

We would like to thank Xiaoqing Chen for her excellent technical support. This work was supported by National Institutes of Health (NIH) grant (AG056060) to ZY, NIH grant (NS102148) to JF and Department of Veterans Affairs Merit Awards (BX002452, BX003831) to JF.

REFERENCES

1. Tanzi RE and Bertram L (2005). Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. *Cell*, 120:545–555. [PubMed: 15734686]
2. Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med*. 8:595–608. [PubMed: 27025652]
3. Haass C and Selkoe DJ (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol*, 8:101–112. [PubMed: 17245412]
4. Selkoe DJ (2002). Alzheimer's disease is a synaptic failure. *Science* 298:789–791. [PubMed: 12399581]
5. Spires-Jones TL and Hyman BT (2014). The intersection of amyloid beta and tau at synapses in Alzheimer's disease. *Neuron* 82:756–771. [PubMed: 24853936]
6. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* 349:704–706. [PubMed: 1671712]
7. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, et al. (2008). A new amyloid mu variant favoring oligomerization in Alzheimer's-type dementia. *Annals of Neurology*, 63:377–387. [PubMed: 18300294]
8. Zhang SC, Wernig M, Duncan ID, Brustle O, and Thomson JA (2001). In vitro differentiation of transplantable neural precursors from human embryonic stem cells. *Nat Biotechnol*, 19:1129–1133. [PubMed: 11731781]
9. Gerrard L, Rodgers L, and Cui W (2005). Differentiation of human embryonic stem cells to neural lineages in adherent culture by blocking bone morphogenetic protein signaling. *Stem Cells*, 23:1234–1241. [PubMed: 16002783]
10. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, and Studer L (2009b). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nature Biotechnology*, 27:485–485.
11. Shi YC, Kirwan P, and Livesey FJ (2012). Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. *Nature Protocols*, 7:1836–1846. [PubMed: 22976355]
12. Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, et al. (2011). Modeling familial Alzheimer's disease with induced pluripotent stem cells. *Hum Mol Genet*, 20: 4530–4539. [PubMed: 21900357]
13. Vazin T, Ball KA, Lu H, Park H, Ataeijannati Y, Head-Gordon T, Poo MM, Schaffer DV (2014). Efficient derivation of cortical glutamatergic neurons from human pluripotent stem cells: A model system to study neurotoxicity in Alzheimer's disease. *Neurobiology of Disease*, 62:62–72. [PubMed: 24055772]
14. Nieweg K, Andreyeva A, van Stegen B, Tanriover G, and Gottmann K (2015). Alzheimer's disease-related amyloid-beta induces synaptotoxicity in human iPS cell-derived neurons. *Cell Death Dis*, 6:e1709. [PubMed: 25837485]

15. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat Med* 14:837–842. [PubMed: 18568035]
16. Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, et al. (2009). Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (A β) assembly from Alzheimer disease brains. *J Biol Chem*, 284:32895–32905. [PubMed: 19759000]
17. Qiang L, Fujita R, Abeliovich A (2013) Remodeling neurodegeneration: somatic cell reprogramming-based models of adult neurological disorders. *Neuron*. 78:957–69. [PubMed: 23791192]
18. Arber C, Lovejoy C, and Wray S (2017). Stem cell models of Alzheimer's disease: progress and challenges. *Alzheimers Research & Therapy*, 9.
19. Mehler MF (2008). Epigenetic principles and mechanisms underlying nervous system functions in health and disease. *Prog Neurobiol*, 86:305–341. [PubMed: 18940229]
20. Lardenoije R, Iatrou A, Kenis G, Kompotis K, Steinbusch HW, Mastroeni D, et al. (2015) The epigenetics of aging and neurodegeneration. *Prog Neurobiol* 131:21–64. [PubMed: 26072273]
21. Mitchell A, Roussos P, Peter C, Tsankova N, & Akbarian S (2014). The future of neuroepigenetics in the human brain. *Prog Mol Biol Transl Sci*, 128:199–228. [PubMed: 25410546]
22. Woldemichael BT, Bohacek J, Gapp K, and Mansuy IM (2014). Epigenetics of memory and plasticity. *Prog Mol Biol Transl Sci*, 122:305–340. [PubMed: 24484706]
23. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. (2007). High-resolution profiling of histone methylations in the human genome. *Cell*, 129:823–837. [PubMed: 17512414]
24. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, et al. (2007). Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. *Nat Genet*, 39:311–318. [PubMed: 17277777]
25. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, and Studer L (2009a). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat Biotechnol*, 27:275–280. [PubMed: 19252484]
26. Wei J, Graziane NM, Wang H, Zhong P, Wang Q, Liu W, Hayashi-Takagi A, Korth C, Sawa A, Brandon NJ, Yan Z (2014). Regulation of N-methyl-D-aspartate receptors by disrupted-in-schizophrenia-1. *Biol Psychiatry*, 75:414–424. [PubMed: 23906531]
27. Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, Rea S, Mechtler K, Kowalski JA, Homon CA, Kelly TA, Jenuwein T (2007) Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. *Mol Cell*. 25:473–81. [PubMed: 17289593]
28. Gu Z, Liu W, and Yan Z (2009). {beta}-Amyloid impairs AMPA receptor trafficking and function by reducing Ca²⁺/calmodulin-dependent protein kinase II synaptic distribution. *J Biol Chem*, 284: 10639–10649. [PubMed: 19240035]
29. Jiang H, Ren Y, Yuen EY, Zhong P, Ghaedi M, Hu Z, Azabdaftari G, Nakaso K, Yan Z, Feng J (2012) Parkin controls dopamine utilization in human midbrain dopaminergic neurons. *Nature Communications* 3:668.
30. Jiang H, Xu Z, Zhong P, Ren Y, Liang G, Schilling HA, Hu Z, Zhang Y, Wang X, Chen S, Yan Z, Feng J (2015) Cell cycle and p53 gate the direct conversion of human fibroblasts to dopaminergic neurons. *Nature Communications* 6:10100.
31. Xu Z, Jiang H, Zhong P, Yan Z, Chen SD, Feng J (2016) Direct conversion of human fibroblasts to induced serotonergic neurons. *Molecular Psychiatry* 21:62–70. [PubMed: 26216300]
32. Zhong P, Hu Z, Jiang H, Yan Z, Feng J (2017) Dopamine induces oscillatory activity in human midbrain neurons with Parkin mutations. *Cell Reports* 19:1033–1044. [PubMed: 28467897]
33. Lithner CU, Lacor PN, Zhao WQ, Mustafiz T, Klein WL, Sweatt JD, Hernandez CM (2013) Disruption of neocortical histone H3 homeostasis by soluble A β : implications for Alzheimer's disease. *Neurobiol Aging*. 34:2081–90. [PubMed: 23582659]
34. Zheng Y, Liu A, Wang ZJ, Cao Q, Wang W, Lin L, Ma K, Zhang F, Wei J, Matas E, Cheng J, Chen GJ, Wang X, Yan Z (2019) Inhibition of EHMT1/2 rescues synaptic and cognitive functions for Alzheimer's disease. *Brain* 142:787–807. [PubMed: 30668640]

35. Poon A, Zhang Y, Chandrasekaran A, Phanthong P, Schmid B, Nielsen TT, Freude KK (2017) Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges. *New Biotechnol.* 39(Pt B):190–198.
36. Kim H, Yoo J, Shin J, Chang Y, Jung J, Jo DG, Kim J, Jang W, Lengner CJ, Kim BS, Kim J (2017) Modelling APOE ε3/4 allele-associated sporadic Alzheimer's disease in an induced neuron. *Brain.* 140:2193–2209. [PubMed: 28899010]
37. Espuny-Camacho I, Arranz AM, Fiers M, Snellinx A, Ando K, Munck S, Bonnefont J, Lambot L, Corthout N, Omodho L, Vanden Eynden E, Radaelli E, Tesseur I, Wray S, Ebner A, Hardy J, Leroy K, Brion JP, Vanderhaeghen P, De Strooper B (2017) Hallmarks of Alzheimer's Disease in Stem-Cell-Derived Human Neurons Transplanted into Mouse Brain. *Neuron.* 93:1066–1081.e8. [PubMed: 28238547]
38. Seo J, Kritskiy O, Watson LA, Barker SJ, Dey D, Raja WK, Lin YT, Ko T, Cho S, Penney J, Silva MC, Sheridan SD, Lucente D, Gusella JF, Dickerson BC, Haggarty SJ, Tsai LH (2017) Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia. *J Neurosci.* 37:9917–9924. [PubMed: 28912154]
39. Choi SH, Kim YH, Quinti L, Tanzi RE, Kim DY (2016) 3D culture models of Alzheimer's disease: a road map to a "cure-in-a-dish". *Mol Neurodegener.* 11:75. [PubMed: 27938410]
40. Robbins JP, Price J (2017) Human induced pluripotent stem cells as a research tool in Alzheimer's disease. *Psychol Med.* 47:2587–2592. [PubMed: 28805182]
41. Imm J, Kerrigan TL, Jeffries A, Lunnon K (2017) Using induced pluripotent stem cells to explore genetic and epigenetic variation associated with Alzheimer's disease. *Epigenomics.* 9:1455–1468. [PubMed: 28969469]
42. Millan MJ (2014) The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity? *Dialogues Clin Neurosci.* 16:373–93. [PubMed: 25364287]
43. Fischer A, Sananbenesi F, Mungenast A, Tsai LH (2010) Targeting the correct HDAC(s) to treat cognitive disorders. *Trends Pharmacol Sci.* 31:605–17. [PubMed: 20980063]
44. Gräff J, Tsai LH (2013) The potential of HDAC inhibitors as cognitive enhancers. *Annu Rev Pharmacol Toxicol.* 53:311–30. [PubMed: 23294310]
45. Fischer A (2014) Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue? *Neuropharmacology.* 80:95–102. [PubMed: 24486385]
46. Coppède F (2014) The potential of epigenetic therapies in neurodegenerative diseases. *Front Genet.* 5:220. [PubMed: 25071843]
47. Greer EL and Shi Y (2012) Histone methylation: a dynamic mark in health, disease and inheritance. *Nature Reviews Genetics* 13:343–357.
48. Anderson KW, Turko IV (2015) Histone post-translational modifications in frontal cortex from human donors with Alzheimer's disease. *Clin Proteomics.* 12:26. [PubMed: 26435705]
49. Ting JT, Kelley BG, Lambert TJ, Cook DG, and Sullivan JM (2007). Amyloid precursor protein overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanisms. *Proc Natl Acad Sci U S A*, 104(1), 353–358. [PubMed: 17185415]
50. Parodi J, Sepulveda FJ, Roa J, Opazo C, Inestrosa NC, and Aguayo LG (2010). Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. *J Biol Chem*, 285:2506–2514. [PubMed: 19915004]
51. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, and Malinow R (2006). AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. *Neuron*, 52:831–843. [PubMed: 17145504]
52. Kleefstra T, Brunner HG, Amiel J, Oudakker AR, Nillesen WM, Magee A, et al. (2006) Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome. *Am J Hum Genet.* 79:370–7. [PubMed: 16826528]
53. Kleefstra T, Kramer JM, Neveling K, Willemsen MH, Koemans TS, Vissers LE, et al. (2012) Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability. *Am J Hum Genet.* 91:73–82. [PubMed: 22726846]

Figure 1.

Generation of human cortical neurons from human embryonic stem (hES) cells. (A-D) Images of distinct stages of *in vitro* differentiation of hES cells, including human ES cells (A), embryoid bodies (EBs, B), neuroepithelial cells (C) and neurons (DIV40, D). (E) Images of neuroepithelial cells (DIV 20) immunostained for neuroectodermal differentiation marker PAX6 (green), neural stem cell marker Nestin (red) and DAPI (blue). (F) Images of hES cell-derived neurons (DIV 120) immunostained for neuronal marker Tuj1 (green), dendritic marker MAP2 (red) and DAPI (blue). (G) Images of hES cell-derived neurons

(DIV 120) immunostained for Tuj1 (green), glutamatergic neuronal marker vGluT1 (red) and DAPI (blue). Scale bar: 20 μ m.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 2. Electrophysiological characterization of human ES cells-derived mature cortical neurons (DIV110). **(A)** Representative traces of voltage-dependent Na^+ and K^+ currents in response to depolarization steps. **(B)** Representative traces of voltage-dependent Ca^{2+} currents in response to depolarization protocols. **(C)** Action potentials in response to current injections. **(D)** Representative traces of whole-cell AMPA- and NMDA-elicited ionic currents. **(E)** Representative traces of spontaneous and miniature excitatory postsynaptic currents. **(F)** Representative traces of large rhythmic network activity. **(G)** Representative traces of spontaneous action potentials.

Figure 3.

The histone methyltransferase *EHMT1/2* was elevated in human cortical neurons and rat neuronal cultures. (A, B) qPCR data on the mRNA level of *EHMT1* and *EHMT2* in human ES cells-derived mature cortical neurons (A) and rat cortical cultures (B) without or with the treatment of Aβ oligomers (1 μM, 3 days). *: p < 0.05, t-test.

Figure 4.

A β treatment decreased AMPAR current density in human cortical neurons and rat neuronal cultures, which was rescued by the EHMT inhibitor BIX01294. (A, C) Representative traces of AMPAR-mediated ionic currents in human cortical neurons (A) or rat cultures (C) without or with the A β exposure (1 μ M, 3 days) and the subsequent BIX01294 treatment (0.5 μ M, 12 hrs). (B, D) Bar graph (mean $\pm$ SEM) of AMPAR current density in different groups of human cortical neurons (B) or rat cultures (D). *: $p < 0.05$, ANOVA.

Figure 5.

Aβ treatment decreased AMPAR-mediated synaptic transmission in human cortical neurons and rat neuronal cultures, which was rescued by the EHMT inhibitor BIX01294. (A, C, E) Representative traces of sEPSC (A) and mEPSC (C, E) in human cortical neurons (A, C) or rat cultures (E) without or with the Aβ exposure (1 μM, 3 days) and the subsequent BIX01294 treatment (0.5 μM, 12 hrs). (B, D, F) Bar graph (mean ± SEM) of sEPSC

frequency & amplitude (B) and mEPSC frequency & amplitude (D, F) in different groups of human cortical neurons (B, D) or rat cultures (F). *: $p < 0.05$, **: $p < 0.01$, ANOVA.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript